Formulation Development
MBX Biosciences Raises $63.5 Million to Advance Precision Endocrine Peptide Platform
MBX Biosciences, Inc. recently announced a $63.5-million Series C financing led by Deep Track Capital, with participation from new investors Driehaus Capital Management and funds…
Cresset Collaborates With Enamine to Enable the Design of Exciting New Targeted Protein Degraders
Cresset recently announced an extension of the global collaboration with Enamine, the world’s leading chemical and biological contract research organization and producer of novel building…
Shapiro Administration Invests Nearly $3 Million to Bring Adare Pharma Solutions’ Headquarters to Pennsylvania
Governor Josh Shapiro recently announced the Commonwealth is investing nearly $3 million in Adare Pharma Solutions to support the life sciences company’s growth and headquarters relocation…
FDA Accepted BLA for the First & Only Ticagrelor Reversal Agent for Filing & Priority Review
SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and…
DiamiR Biosciences Secures Patent Covering the Use of microRNA Biomarkers From Bodily Fluids for Differential Diagnosis of ALS
DiamiR recently announced its European Patent Application No. 17 771018.3 titled Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases was…
Bayer Submits NDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
Bayer recently announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the US FDA for the treatment of…
FDA Approves Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Limited recently announced the US FDA approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia…
AC Immune Unveils Novel Therapeutic ADC Technology for Improved Efficacy in Neurodegenerative Diseases
AC Immune SA recently unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer Antibody Drug Conjugate) in an oral presentation at the annual…
GeoVax Announces Phase 2 Plans for Cancer Therapy Following Clinical Advisory Committee Review
GeoVax Labs, Inc. recently announced the next steps for the clinical development of its Gedeptin cancer therapy, following a clinical advisory committee review. GeoVax and…
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease
Vaccinex, Inc. recently announced positive results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD. Topline results were presented by Eric Siemers,…
GSK Leverages Genedata Biologics as End-to-End Automation & Data Science Platform
Genedata recently announced GSK, a leading biopharma company, has extended the use of Genedata Biologics to new application areas in data sciences, analytics, and R&D automation.…
Ocular Therapeutix Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
Ocular Therapeutix, Inc. recently announced the first patients have been enrolled in the Phase 3 SOL-R clinical trial evaluating repeat dosing of AXPAXLI (axitinib intravitreal…
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX2-73 in Fragile X Syndrome (Major Cause of Autism)
Anavex Life Sciences Corp. recently reported positive preclinical results in directly to humans’ translatable biomarkers for individuals with FXS for ANAVEX2-73 (blarcamesine), in a disease…
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer. OVATION 2 is…
Sapio Sciences & Zifo Announce Strategic Partnership
Sapio Sciences and Zifo recently announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical…
Dosing Completed in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate
Incannex Healthcare Inc. recently announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. IHL-42X comprises two drugs, dronabinol (synthetic delta-9-tetrahydrocannabinol…
CordenPharma Invests Nearly One Billion in Transformational Peptide Platform Expansion in the US & Europe
CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology…
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. recently announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company developing therapeutic cells for…
Alcami Unveils New Conditions & Services at State-of-the-Art Pharma Storage Facility in Garner
Alcami Corporation has significantly expanded the cold, stability, and custom storage options at its new 65,000 ft2 state-of-the-art pharma storage facility in Garner. With a…
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison…
